News
Viamet and Mycoses Study Group Education & Research Consortium Establish Collaboration to Advance a Novel Therapy for Cryptococcal Meningitis
Viamet Pharmaceuticals, Inc. and the Mycoses Study Group Education & Research Consortium (MSGERC) announced the establishment of a strategic collaboration to advance a novel therapy for cryptococcal meningitis and other life-threatening fungal infections. This collaboration will combine the antifungal drug discovery and development expertise of Viamet with the strategic clinical development expertise of the MSGERC.